Trial Profile
A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 Positive Early or Locally Advanced Breast Cancer Who Have Completed the SB3-G31-BC
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Feb 2024
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary) ; Antineoplastics
- Indications Adenocarcinoma; Advanced breast cancer; Early breast cancer; HER2 positive breast cancer
- Focus Adverse reactions; Registrational
- Sponsors Samsung Bioepis
- 08 Dec 2021 According to Samsung Bioepis Media Release, during the follow-up study, the protocol was amended to include additional patients who originally were enrolled in the Phase 3 study but had not been followed in the observational study, in order to collect a larger sample of survival data, and 171 patients were additionally enrolled.
- 08 Dec 2021 Results presented in the Samsung Bioepis Media Release.
- 07 Jan 2021 This trial has been completed in Bulgaria (Global End Date: 11 Dec 2020), according to European Clinical Trials Database record.